AAPL281.62-2.17 (-0.76%) ▼|ABBV253.74+0.39 (+0.15%) ▲|ABT93.48-0.64 (-0.68%) ▼|ACN125.21-3.77 (-2.92%) ▼|ADBE205.52+2.79 (+1.38%) ▲|AMAT697.81+70.97 (+11.32%) ▲|AMD537.18+15.60 (+2.99%) ▲|AMGN359.53+1.20 (+0.33%) ▲|AMT169.07-6.52 (-3.71%) ▼|AMZN240.98+8.29 (+3.56%) ▲|AVGO375.57+10.55 (+2.89%) ▲|AXP341.59+1.23 (+0.36%) ▲|BA215.39-1.86 (-0.86%) ▼|BAC58.12+0.24 (+0.41%) ▲|BKNG183.41+1.95 (+1.07%) ▲|BLK953.48-11.23 (-1.16%) ▼|BMY57.68+0.16 (+0.28%) ▲|BNY144.55+0.99 (+0.69%) ▲|BRK-B496.38-2.28 (-0.46%) ▼|C143.43+1.67 (+1.17%) ▲|CAT1,030.95+33.48 (+3.36%) ▲|CL91.54-0.53 (-0.58%) ▼|CMCSA24.60+1.43 (+6.17%) ▲|COF203.27-0.73 (-0.36%) ▼|COP104.98-0.99 (-0.93%) ▼|COST944.63-7.91 (-0.83%) ▼|CRM158.08-0.29 (-0.18%) ▼|CSCO117.87+4.10 (+3.60%) ▲|CVS103.62-0.72 (-0.69%) ▼|CVX169.70-1.36 (-0.80%) ▼|DE616.09+2.85 (+0.46%) ▲|DHR192.02-4.17 (-2.13%) ▼|DIS98.89+0.10 (+0.10%) ▲|DUK127.92-0.48 (-0.37%) ▼|EMR142.90-0.60 (-0.41%) ▼|FDX324.30+5.77 (+1.81%) ▲|GD349.37+2.66 (+0.77%) ▲|GE373.19+4.19 (+1.13%) ▲|GEV1,103.00+57.83 (+5.53%) ▲|GILD125.85-2.03 (-1.59%) ▼|GM78.28+0.18 (+0.23%) ▲|GOOG351.10+16.41 (+4.90%) ▲|GOOGL353.10+15.71 (+4.66%) ▲|GS1,025.85+6.24 (+0.61%) ▲|HD349.50+0.64 (+0.18%) ▲|HON236.93-6.49 (-2.66%) ▼|IBM276.12+4.49 (+1.65%) ▲|INTC130.75+2.43 (+1.89%) ▲|INTU267.01-0.72 (-0.27%) ▼|ISRG407.62+3.35 (+0.83%) ▲|JNJ256.32+1.66 (+0.65%) ▲|JPM331.28+2.23 (+0.68%) ▲|KO82.24-0.40 (-0.48%) ▼|LIN509.98-9.64 (-1.86%) ▼|LLY1,219.25+11.13 (+0.92%) ▲|LMT505.29-2.11 (-0.42%) ▼|LOW220.59-1.89 (-0.85%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA511.37+12.35 (+2.47%) ▲|MCD267.39-2.38 (-0.88%) ▼|MDLZ59.84-0.95 (-1.56%) ▼|MDT81.29+0.31 (+0.38%) ▲|META565.86+15.61 (+2.84%) ▲|MMM163.37-0.65 (-0.39%) ▼|MO73.31-0.48 (-0.65%) ▼|MRK128.43-0.23 (-0.18%) ▼|MS213.93+1.90 (+0.89%) ▲|MSFT369.26-3.71 (-0.99%) ▼|MU1,114.47-17.87 (-1.58%) ▼|NEE87.92-0.64 (-0.72%) ▼|NFLX74.32+0.51 (+0.69%) ▲|NKE41.47+0.72 (+1.75%) ▲|NOW100.20+1.86 (+1.89%) ▲|NVDA194.17+1.64 (+0.85%) ▲|ORCL148.58+0.05 (+0.03%) ▲|PEP137.89-3.50 (-2.48%) ▼|PFE24.25-0.04 (-0.16%) ▼|PG147.25-1.77 (-1.19%) ▼|PLTR116.62+3.69 (+3.26%) ▲|PM180.32-0.46 (-0.25%) ▼|QCOM191.17+1.78 (+0.94%) ▲|RTX188.08+0.09 (+0.05%) ▲|SBUX104.23-0.38 (-0.36%) ▼|SCHW90.61-0.06 (-0.07%) ▼|SO96.58-0.58 (-0.60%) ▼|SPG227.21+0.32 (+0.14%) ▲|T21.78-0.94 (-4.15%) ▼|TMO502.85-10.18 (-1.98%) ▼|TMUS175.40-7.28 (-3.99%) ▼|TSLA409.28+29.57 (+7.79%) ▲|TXN289.81+4.39 (+1.54%) ▲|UBER75.02-1.18 (-1.55%) ▼|UNH417.51-10.38 (-2.43%) ▼|UNP270.30+1.95 (+0.73%) ▲|UPS107.70-0.44 (-0.41%) ▼|USB61.31+0.40 (+0.66%) ▲|V341.90+5.67 (+1.69%) ▲|VZ43.85-2.69 (-5.78%) ▼|WFC84.09+0.23 (+0.27%) ▲|WMT114.36-1.33 (-1.15%) ▼|XOM136.74+0.20 (+0.15%) ▲|AAPL281.62-2.17 (-0.76%) ▼|ABBV253.74+0.39 (+0.15%) ▲|ABT93.48-0.64 (-0.68%) ▼|ACN125.21-3.77 (-2.92%) ▼|ADBE205.52+2.79 (+1.38%) ▲|AMAT697.81+70.97 (+11.32%) ▲|AMD537.18+15.60 (+2.99%) ▲|AMGN359.53+1.20 (+0.33%) ▲|AMT169.07-6.52 (-3.71%) ▼|AMZN240.98+8.29 (+3.56%) ▲|AVGO375.57+10.55 (+2.89%) ▲|AXP341.59+1.23 (+0.36%) ▲|BA215.39-1.86 (-0.86%) ▼|BAC58.12+0.24 (+0.41%) ▲|BKNG183.41+1.95 (+1.07%) ▲|BLK953.48-11.23 (-1.16%) ▼|BMY57.68+0.16 (+0.28%) ▲|BNY144.55+0.99 (+0.69%) ▲|BRK-B496.38-2.28 (-0.46%) ▼|C143.43+1.67 (+1.17%) ▲|CAT1,030.95+33.48 (+3.36%) ▲|CL91.54-0.53 (-0.58%) ▼|CMCSA24.60+1.43 (+6.17%) ▲|COF203.27-0.73 (-0.36%) ▼|COP104.98-0.99 (-0.93%) ▼|COST944.63-7.91 (-0.83%) ▼|CRM158.08-0.29 (-0.18%) ▼|CSCO117.87+4.10 (+3.60%) ▲|CVS103.62-0.72 (-0.69%) ▼|CVX169.70-1.36 (-0.80%) ▼|DE616.09+2.85 (+0.46%) ▲|DHR192.02-4.17 (-2.13%) ▼|DIS98.89+0.10 (+0.10%) ▲|DUK127.92-0.48 (-0.37%) ▼|EMR142.90-0.60 (-0.41%) ▼|FDX324.30+5.77 (+1.81%) ▲|GD349.37+2.66 (+0.77%) ▲|GE373.19+4.19 (+1.13%) ▲|GEV1,103.00+57.83 (+5.53%) ▲|GILD125.85-2.03 (-1.59%) ▼|GM78.28+0.18 (+0.23%) ▲|GOOG351.10+16.41 (+4.90%) ▲|GOOGL353.10+15.71 (+4.66%) ▲|GS1,025.85+6.24 (+0.61%) ▲|HD349.50+0.64 (+0.18%) ▲|HON236.93-6.49 (-2.66%) ▼|IBM276.12+4.49 (+1.65%) ▲|INTC130.75+2.43 (+1.89%) ▲|INTU267.01-0.72 (-0.27%) ▼|ISRG407.62+3.35 (+0.83%) ▲|JNJ256.32+1.66 (+0.65%) ▲|JPM331.28+2.23 (+0.68%) ▲|KO82.24-0.40 (-0.48%) ▼|LIN509.98-9.64 (-1.86%) ▼|LLY1,219.25+11.13 (+0.92%) ▲|LMT505.29-2.11 (-0.42%) ▼|LOW220.59-1.89 (-0.85%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA511.37+12.35 (+2.47%) ▲|MCD267.39-2.38 (-0.88%) ▼|MDLZ59.84-0.95 (-1.56%) ▼|MDT81.29+0.31 (+0.38%) ▲|META565.86+15.61 (+2.84%) ▲|MMM163.37-0.65 (-0.39%) ▼|MO73.31-0.48 (-0.65%) ▼|MRK128.43-0.23 (-0.18%) ▼|MS213.93+1.90 (+0.89%) ▲|MSFT369.26-3.71 (-0.99%) ▼|MU1,114.47-17.87 (-1.58%) ▼|NEE87.92-0.64 (-0.72%) ▼|NFLX74.32+0.51 (+0.69%) ▲|NKE41.47+0.72 (+1.75%) ▲|NOW100.20+1.86 (+1.89%) ▲|NVDA194.17+1.64 (+0.85%) ▲|ORCL148.58+0.05 (+0.03%) ▲|PEP137.89-3.50 (-2.48%) ▼|PFE24.25-0.04 (-0.16%) ▼|PG147.25-1.77 (-1.19%) ▼|PLTR116.62+3.69 (+3.26%) ▲|PM180.32-0.46 (-0.25%) ▼|QCOM191.17+1.78 (+0.94%) ▲|RTX188.08+0.09 (+0.05%) ▲|SBUX104.23-0.38 (-0.36%) ▼|SCHW90.61-0.06 (-0.07%) ▼|SO96.58-0.58 (-0.60%) ▼|SPG227.21+0.32 (+0.14%) ▲|T21.78-0.94 (-4.15%) ▼|TMO502.85-10.18 (-1.98%) ▼|TMUS175.40-7.28 (-3.99%) ▼|TSLA409.28+29.57 (+7.79%) ▲|TXN289.81+4.39 (+1.54%) ▲|UBER75.02-1.18 (-1.55%) ▼|UNH417.51-10.38 (-2.43%) ▼|UNP270.30+1.95 (+0.73%) ▲|UPS107.70-0.44 (-0.41%) ▼|USB61.31+0.40 (+0.66%) ▲|V341.90+5.67 (+1.69%) ▲|VZ43.85-2.69 (-5.78%) ▼|WFC84.09+0.23 (+0.27%) ▲|WMT114.36-1.33 (-1.15%) ▼|XOM136.74+0.20 (+0.15%) ▲|
30.5 C
New York
Monday, June 29, 2026

Tag: patients

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research...

From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI...

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

The evolving peanut allergy treatment market landscape features clinical trials led by DBV Technologies (Viaskin Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual...

Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

 Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time           SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.

Senior Living Members Set to Receive Even Greater Value as Navigator Group Purchasing, Inc. Extends Strategic Partnership with Foodbuy

PARSIPPANY, N.J., July 16, 2025 /PRNewswire/ -- Navigator Group Purchasing, Inc., a Managed Health Care Associates, Inc. (MHA) Company, and the largest and most experienced...

Blue Circle Health expands type 1 diabetes care program to Louisiana

Free type 1 diabetes clinical care, education, and support program for adults is now operating in Louisiana.Designed to improve health outcomes and empower individuals...

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

CeraVe Marks 20 Years of Therapeutic Skincare Developed with Dermatologists with Five New Innovations

Top Skincare Brand Adds Five Products Formulated to Support the Skin Barrier NEW YORK, July 16, 2025 /PRNewswire/ -- CeraVe, the #1 dermatologist-recommended1 and pediatrician-recommended2 skincare...

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients